Yorke Justin W. - 03 Dec 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Director
Signature: s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 03 Dec 2021
Net transactions value: -$46,383
Form type: 4
Filing time: 07 Dec 2021, 15:36:14 UTC
Previous filing: 31 Mar 2022
Next filing: 31 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Sale	$26,599	-5,500	-1%	$4.84	538,617	03 Dec 2021	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC	F1
transaction	PCSA	Common Stock	Sale	$19,784	-4,200	-0.78%	$4.71	534,417	06 Dec 2021	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC	F2
holding	PCSA	Common Stock						9,323	03 Dec 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.8001 to $5.01, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.5601 to $4.80, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.8001 to $5.01, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.5601 to $4.80, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.